On this page
Mucopolysaccharidosis type IVA (Morquio A)
Morquio A is a rare genetic condition where the body cannot properly process certain large sugar molecules, called glycosaminoglycans. This leads to their build-up in cells, particularly in bone and cartilage, causing progressive skeletal and connective tissue problems. It affects both males and females.
Available at Jeen Health
Clinical tests that include this
Overview
Mucopolysaccharidosis type IVA, also known as Morquio A, is a rare inherited condition belonging to a group of disorders called lysosomal storage diseases. In Morquio A, the body cannot effectively break down complex sugar molecules called glycosaminoglycans (GAGs), specifically keratan sulphate [PMID:33671049]. These GAGs are essential components of connective tissues, including cartilage, bone, and skin.
Normally, GAGs are continuously recycled within specialised cellular compartments called lysosomes. In Morquio A, a specific enzyme required for this recycling process is deficient or not working correctly. This leads to an accumulation of keratan sulphate within cells throughout the body, causing cellular dysfunction and progressive damage, especially in the skeleton, eyes, and heart [PMID:33671049]. The estimated prevalence of Morquio A is approximately 1 in 200,000 live births.
Symptoms typically become apparent in early childhood, often between 1 and 3 years of age, though the severity and rate of progression can vary significantly between individuals. Early diagnosis and management are important for optimising care and quality of life.
Symptoms & clinical features
The symptoms of Morquio A primarily affect the skeleton and connective tissues, leading to a range of physical challenges. Skeletal abnormalities are common and often include short stature, a short trunk, and a distinctive 'barrel' chest. Spinal problems such as kyphoscoliosis (a curvature of the spine) and atlantoaxial instability (weakness in the joint between the first two neck vertebrae) can lead to spinal cord compression, which may cause pain, weakness, or difficulties with movement [PMID:24074288].
Other common features include joint hypermobility (very flexible joints) which can paradoxically be accompanied by joint pain and stiffness over time. Bone changes in the hips and knees are also typical. Beyond the skeleton, individuals may experience corneal clouding, which can affect vision, and hearing impairment. Respiratory issues can arise due to skeletal changes affecting the rib cage and may be exacerbated by airway narrowing. Heart valve problems can also occur in some individuals.
Video: Genetics 101
Affected organs
Morquio A primarily affects the skeletal system, leading to widespread bone and joint abnormalities throughout the body. The spine, ribs, hips, and long bones of the arms and legs are particularly impacted. Connective tissues, which are crucial for supporting and connecting other tissues and organs, are also significantly affected, including cartilage, tendons, and ligaments.
Beyond the skeleton, other organs can be involved. The eyes may develop corneal clouding, potentially affecting vision. The ears can experience hearing loss. The heart may be affected by valvular disease. Respiratory function can be compromised due to changes in the chest wall and airways. The liver and spleen can sometimes be enlarged, though this is less prominent than in some other mucopolysaccharidoses.
Risks & severity
The severity of Morquio A can vary considerably, even within the same family, ranging from more severe forms with earlier onset and rapid progression to milder forms with later onset and slower progression. While some individuals may experience significant skeletal deformity and organ involvement, others might have milder symptoms that allow for greater mobility and fewer complications.
Key risks include progressive spinal cord compression due to atlantoaxial instability or kyphoscoliosis, which can lead to neurological problems if not managed. Respiratory complications due to skeletal changes and airway issues are also a significant concern. Cardiac involvement, such as heart valve problems, can develop over time. The condition is progressive, meaning symptoms tend to worsen over a person's lifetime.
Genetic causes
Morquio A is caused by pathogenic variants (sometimes called mutations) in the *GALNS* gene. The *GALNS* gene provides instructions for making an enzyme called N-acetylgalactosamine-6-sulfatase, also known as GALNS. This enzyme is primarily found in lysosomes, which are small compartments within cells responsible for recycling waste products.
The GALNS enzyme plays a critical role in breaking down specific complex sugar molecules called glycosaminoglycans, particularly keratan sulphate [PMID:33671049]. When the *GALNS* gene has a pathogenic variant, the enzyme is either deficient or does not function correctly. As a result, keratan sulphate cannot be broken down and instead accumulates within the lysosomes of various cells and tissues throughout the body, leading to the cellular dysfunction and clinical features characteristic of Morquio A [PMID:24074288].
- GALNS galactosamine (N-acetyl)-6-sulfataseThe GALNS gene provides instructions for an enzyme called N-acetylgalactosamine 6-sulfatase, which plays a crucial role in breaking down specific large sugar molecules within cells.
Inheritance pattern
Morquio A is inherited in an autosomal recessive pattern. This means that a child must inherit two copies of a pathogenic variant in the *GALNS* gene - one from each parent - to develop the condition. Individuals who inherit only one pathogenic variant are known as carriers.
Carriers typically do not show any symptoms of Morquio A because they have one working copy of the *GALNS* gene, which is usually sufficient to produce enough functional enzyme. If two carriers have a child together, there is a 25% (1 in 4) chance with each pregnancy that the child will inherit two pathogenic variants and develop Morquio A. There is a 50% (2 in 4) chance the child will be a carrier like their parents, and a 25% (1 in 4) chance the child will inherit two working copies of the gene and will not be a carrier or have the condition.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
The diagnosis of Morquio A is usually suspected based on characteristic clinical signs and symptoms, particularly the distinctive skeletal abnormalities and joint issues. Initial biochemical tests can support the diagnosis by measuring levels of keratan sulphate in urine [PMID:33671049]. Elevated levels of this GAG in urine are a strong indicator of Morquio A.
Confirmation of the diagnosis requires genetic testing to identify pathogenic variants in the *GALNS* gene. This can be performed through an NHS Genomic Medicine Service (GMS) pathway, often initiated by a clinical geneticist or a specialist paediatrician. Genetic testing is covered by the R-code R14 (Lysosomal storage disorders) or R21 (Inherited metabolic disorders). A referral to a clinical genetics service is usually made for individuals with suspected Morquio A and for their families for genetic counselling.
Management & lifestyle
Management of Morquio A focuses on addressing symptoms, preventing complications, and improving quality of life. It typically involves a multidisciplinary team of specialists, including paediatricians, orthopaedic surgeons, neurologists, ophthalmologists, audiologists, and cardiologists. Regular monitoring is essential to detect and manage complications early.
Specific interventions may include enzyme replacement therapy (ERT), which aims to provide the missing GALNS enzyme to help reduce the accumulation of keratan sulphate [PMID:24074288]. This therapy is usually administered intravenously on a regular basis. Surgical interventions may be necessary for skeletal complications, such as correcting spinal deformities or stabilising the neck to prevent spinal cord compression. Physical therapy and occupational therapy can help maintain mobility and independence. Regular ophthalmological and audiological assessments are important for managing vision and hearing problems. Genetic counselling is offered to affected individuals and their families to provide information about the condition, inheritance, and reproductive options.
UK care pathway
In the UK, suspected cases of Morquio A would typically be referred to a specialist paediatrician or metabolic consultant who can coordinate initial investigations. If a lysosomal storage disorder or inherited metabolic disorder is suspected, a referral to a clinical genetics service or metabolic genetics centre is usually made. This pathway allows for comprehensive assessment, including confirmation through genetic testing, which falls under NHS Genomic Medicine Service (GMS) R-codes such as R14 (Lysosomal storage disorders) or R21 (Inherited metabolic disorders). Genetic counsellors play a crucial role in supporting families, providing information on inheritance, and discussing implications for other family members.
Frequently asked questions
What is the difference between Morquio A and Morquio B?
Morquio A and Morquio B are both types of mucopolysaccharidosis type IV. Morquio A is caused by pathogenic variants in the *GALNS* gene, leading to a deficiency of N-acetylgalactosamine-6-sulfatase. Morquio B is caused by pathogenic variants in a different gene, *GLB1*, affecting a different enzyme called beta-galactosidase. While both affect bone and cartilage, the specific enzyme deficiencies are different.
Can Morquio A be treated?
Yes, there are management strategies and treatments available for Morquio A. Enzyme replacement therapy (ERT) can help reduce the accumulation of keratan sulphate. Supportive care, including orthopaedic surgeries for skeletal issues, physical therapy, and management of other symptoms, is also an important part of treatment to improve quality of life.
How does Morquio A affect lifespan?
The impact on lifespan in Morquio A can vary widely depending on the severity of the condition and the presence of complications, particularly those affecting the spine, heart, and respiratory system. With appropriate management and treatment, individuals with Morquio A can live well into adulthood, though medical care is often ongoing.
Is Morquio A passed down through families?
Yes, Morquio A is an inherited condition. It follows an autosomal recessive pattern of inheritance, meaning a child needs to inherit a pathogenic variant from both parents to develop the condition. Parents who each carry one pathogenic variant are typically unaffected themselves but have a 25% chance of having a child with Morquio A with each pregnancy.
What kind of specialist doctors manage Morquio A?
Managing Morquio A typically involves a team of specialists due to its wide-ranging effects. This team often includes a metabolic consultant, geneticist, orthopaedic surgeon, neurologist, cardiologist, ophthalmologist, audiologist, and physiotherapist. This multidisciplinary approach ensures comprehensive care for all aspects of the condition.